INTRODUCTION
Multidrug-resistant Gram-positive organisms are commonly causative of nosocomial infections and are associated with significant morbidity and mortality [1] . Of particular concern to clinicians, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE) remain sensitive to few antimicrobial agents available for the treatment of serious infections [2] [3] [4] .
Daptomycin and linezolid have been increasingly utilized over the past 15 years, and reduced susceptibility to each of these drugs has emerged among staphylococci and enterococci [5] [6] [7] [8] . Though resistance to these agents is currently rare, expanding the antibiotic armamentarium available for the treatment of serious MRSA and VRE infections has become increasingly important.
Oxazolidinones are a synthetic class of antimicrobials, developed over the past 30 years by numerous pharmaceutical companies [9] .
Linezolid, the first oxazolidinone approved for use in clinical practice, has activity against both multidrug-resistant staphylococci and enterococci. Currently indicated for the treatment of complicated and uncomplicated skin and skin structure infections (cSSSI), community-acquired and nosocomial pneumonia, as well as infections caused by VRE, linezolid has found widespread utilization in clinical practice [10] .
Tedizolid phosphate (formerly torezolid; Cubist Pharmaceuticals) is the first of the next generation of oxazolidinones to obtain Food and Drug Administration (FDA) approval. A number of similarities exist between tedizolid and its predecessor linezolid. However, initial experience with tedizolid has shown advantages in antimicrobial potency against key organisms including those with reduced susceptibility to linezolid, lower incidence of adverse effects over short courses of therapy, and favorable pharmacokinetics. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
STRUCTURE AND MECHANISM OF ANTIMICROBIAL ACTIVITY
Throughout the development of the oxazolidinones, the class pharmacophore was increasingly refined by a series of structureactivity relationship studies [9] . Linezolid demonstrates several structural features strongly associated with enhanced antimicrobial potency. The addition of the N-aryl group (B-ring) to the oxazolidinone ring (A-ring) is essential for activity and is further enhanced by both a meta-fluorine and paraoriented electron withdrawing or unsaturated group (C-ring). Linezolid, as well as a number of oxazolidinones currently undergoing clinical investigation, features an acetamidomethyl sidechain on C-5 of the oxazolidinone ring.
The incorporation of this sidechain has displayed potency benefits among both Grampositive organisms and mycobacterium [11] .
The approval of tedizolid phosphate marks not only the first of a new generation of oxazolidinone antimicrobials, but also a departure from previously held structureactivity relationships ( Fig. 1 ). While earlier studies found a hydroxymethyl sidechain in the C-5 position offered decreased potency, it was later shown that this could be circumvented with the addition of a fourth para-oriented ring structure (D-ring) [12] . It is believed the D-ring structure adds additional sites for hydrogen bonding and further stabilizes interactions with the target site. Interestingly, with these structural features bookending the structure of tedizolid, an antimicrobial activity several fold above that of linezolid was achieved. The utilization of the phosphorylated prodrug, tedizolid phosphate, enables significantly improved solubility in water and excellent oral bioavailability while also masking the C-5 hydroxymethyl from interactions with monoamine oxidase (MAO) [13] . The phosphate group is readily cleaved in blood by serum phosphatase and does not impair antimicrobial potency [9, 14] .
Oxazolidinones exert antimicrobial activity through inhibition of protein synthesis, binding to the V-domain of the 23S rRNA component of the 50S ribosomal subunit. This inhibition produces primarily bacteriostatic antimicrobial activity at clinically relevant concentrations. Extensive interactions between oxazolidinones and the A-site of the peptidyltransferase center (PTC) block the alignment of incoming aminoacyl-tRNA and halt peptide elongation [15] . Although the hypothesized interaction sites for oxazolidinones are at least partially unique to this class of protein synthesis
inhibitors, there appears to be a degree of overlap with other antimicrobials such as chloramphenicol, clindamycin, and streptogramin A [16] . As with other protein synthesis inhibitors such as clindamycin, some studies have suggested that oxazolidinones may decrease the production of certain toxins among staphylococci and streptococci [17, 18] .
However, further investigation will be required to identify the clinical utility of this effect. 
SUSCEPTIBILITY

MECHANISMS OF RESISTANCE
Although it was originally anticipated that the fully synthetic nature of the oxazolidinone class would circumvent preexisting pools of resistance, the first isolates of Gram-positive organisms with resistance to linezolid appeared during preclinical trials [20] . Additionally, a clinical isolate of S. aureus was found to be resistant to linezolid after acquisition of a previously known and naturally occurring resistance mechanism [21] . Emergence of clinical isolates with reduced susceptibility to linezolid has nonetheless remained relatively rare for over a decade. Resistance rates vary slightly by region, but remain under 1% across staphylococci and enterococci. Resistance is most frequently reported in individual patients following repeated or extended exposures to linezolid, although horizontal transfer has led to outbreaks of organisms with reduced linezolid susceptibility at institutions with higher linezolid utilization [8, 22] . Reduced susceptibility to oxazolidinones is most frequently associated with either point mutations within the ribosomal complex or the acquisition of the chloramphenicol-florfenicol resistance (cfr) gene.
Point mutations within either the 23S rRNA or ribosomal proteins L3 and L4 were the first widely recognized mechanisms of reduced oxazolidinone susceptibility. As staphylococci and enterococci typically possess five to six and four to six copies of 23S rRNA genes, respectively, multiple mutations often must be acquired before MIC climb above clinical breakpoints. The G2576T mutation is a [23] . This genetic redundancy may at least in part be responsible for the sustained activity of linezolid. However, single copy mutations have been shown to be relatively stable and possess low fitness cost, making additional mutations and more rapid emergence of resistant isolates possible with multiple exposures to linezolid [24] . This more rapid emergence of resistance has been reported clinically after as few as two courses of linezolid [25] .
L3 and L4 ribosomal proteins are located proximally to the 23S rRNA, and mutations in these proteins appear to disturb the interactions between oxazolidinones and the PTC. This mechanism of resistance may be less common than others among staphylococci and enterococci; however, a recent study of the Center for Disease Control and Prevention's Active Bacterial Core surveillance found L4 mutations to be the only mechanism detected among linezolid-resistant pneumococcus (though only present in 3 of the 45,099 isolates tested) [26] . In staphylococci and enterococci, modifications to L4 in particular appear to have a clinically significant impact on linezolid MIC, leading to a fourfold increase when added to previously susceptible isolates [27] . Additionally, L3 mutations have been shown to restore fitness to organisms with multiple 23S rRNA mutations, as well as dramatically inflate MIC in the presence of the cfr gene [28, 29] .
Perhaps, the most worrisome of these resistance mechanisms is the acquisition of the cfr gene. This gene, previously best known for leading to phenicol-resistant infections in livestock, is often carried on mobile genetic elements and has been shown to be horizontally transferrable [30] . In fact, cfr has now been detected in both Gram-positive and Gram-negative organisms ranging from 
cfr positive (13)
Multiple mechanisms (5) Tedizolid [34] [35] [36] . This is believed to be due to the fact that the hydroxymethyl C-5 sidechain is smaller and more flexible than acetamidomethyl sidechain of linezolid [36] . The preserved potency of tedizolid among cfr isolates suggests it may remain useful against some linezolid-resistant organisms. However, clinical experience has yet to verify this in vitro advantage as clinically significant. [43] . Given the concentrationdependent activity of oxazolidinones, this increased pulmonary exposure of tedizolid may be therapeutically advantageous for the treatment of pulmonary infections.
PHARMACOKINETICS
PHARMACODYNAMICS
Oxazolidinones, including both linezolid and tedizolid, appear to have pharmacodynamic profiles best described by the fAUC 0-24 to MIC ratio (fAUC 0-24 :MIC). Initial modeling with linezolid suggested a pharmacodynamic target of 58 mg h/L, which was subsequently echoed by pharmacodynamic evaluation of linezolid clinical outcomes in the treatment of both skin and soft tissue infections and pneumonia [44, 45] . While early work with tedizolid suggested pharmacodynamic targets of approximately 47 and 20 mg h/L for bacterial stasis in classic neutropenic models of murine thigh infections and pneumonia, respectively, the dose of tedizolid phosphate selected for late-stage clinical trials was significantly lower than that required to meet these targets [46, 47] . This was in large part due to the clinical response observed with 200 mg daily dosing in Phase II trials, and later supported by pharmacodynamic evaluations investigating the impact of granulocytes on the activity of tedizolid. In an assessment of the pharmacodynamics of tedizolid in a non-neutropenic murine thigh infection model, a 16-fold lower dose to achieve bacterial stasis at 24 h was required compared to neutropenic mice. This dose would be estimated to achieve an fAUC 0-24 :MIC of approximately 3 mg h/L [48] . It was also observed that in the presence of granulocytes, tedizolid reduced bacterial burden of MRSA by 3.5 log 10 CFU and 4.7 log 10 CFU at 48 and 72 h, respectively, when accounting for the direct activity of granulocytes without tedizolid therapy [49] . This seemingly bactericidal activity contrasts the normal expectation of bacteriostasis with oxazolidinone treatment. These data, along with the non-inferiority of tedizolid compared to linezolid in Phase II and III clinical trials, support the use of the 200 mg daily dosing of tedizolid for acute bacterial skin and skin structure infections (ABSSSI). Baseline characteristics were similar between studies and treatment groups with the majority of patients being men (63%) with a median age of 44 years [50] [51] [52] . Cellulitis/erysipelas was the most common type of ABSSSI (46%) and was most frequently located on either lower (41%) or upper extremities (34%). The pathogen isolated most frequently was S. aureus (82%), with 43% of those being MRSA and 57% being MSSA. A numerically higher percentage of patients enrolled in ESTABLISH-1 were from North America (81%) compared to those enrolled in ESTABLISH-2 (47%), leading to higher percentages of patients with MRSA isolated in ESTABLISH-1 than ESTABLISH-2 (43% compared to 28%). Tedizolid met the criteria for non-inferiority in both trials, with similar early clinical response in the pooled ITT population of 81.6% for tedizolid and 79.4% for linezolid (95% CI -2.0 to 6.5). This similarity between groups at early clinical response was also seen between all prespecified subgroups, including key causative pathogen, with a response of 85.1% and 80.7% observed against S. aureus for tedizolid and linezolid, respectively. Additionally, secondary end points of clinical response at EOT were also similar between groups with 87.0% for tedizolid and 87.9% for linezolid (95% CI 14.4-2.7), as well as investigator-assessed clinical response at PTE, with a response of 86.7% for tedizolid and 86.8% for linezolid (95% CI -3.8 to 3.6).
EARLY CLINICAL EXPERIENCE
Treatment-emergent adverse events (TEAE)
were reported in 43% of patients overall, with the most common events being nausea, headache, and abscess [50] [51] [52] .
Gastrointestinal adverse events were the most frequently reported and were more likely to occur in the linezolid group (23% compared to 16%; P = 0.0015). A difference in the occurrence of hematologic laboratory abnormalities between groups was also reported. The most prominent difference was seen in the incidence of thrombocytopenia (defined as platelets\150,000 cells/mm 3 ), with 3.7% versus 5.6% (P = 0.585) at 7-9 days, and 4.9% versus 10.8% (P = 0.0003) at 11-13 days for tedizolid and linezolid, respectively. Other hematologic laboratory abnormalities notable were absolute neutrophil counts less than the lower limit of normal reported in 1.9% of those taking tedizolid and 3.3% of those taking linezolid at EOT, and hemoglobin levels less than the lower limit of normal in 28 50 period is hypothesized to allow for mitochondrial recovery and may account for the lack of neuropathies observed in vivo. As with linezolid, the potential of neuropathies associated with tedizolid therapy will largely be defined by Phase IV experience.
An additional safety concern among the oxazolidinone class is the ability of these [13] . Finally, tedizolid was compared to linezolid in a murine serotonergic model to evaluate the effect on mouse head twitching seen when these oxazolidinones were given with other medications known to increase serotonin. This model showed that tedizolid did not increase head twitch response even when dosed at 25 times the normal human dose. Based on these studies, tedizolid is thought to have a low probability of causing MAO-related adverse events when given in combination with serotonin-increasing medications. However, clinical experience with this potential adverse effect of tedizolid is currently lacking as patients on medications such as these were excluded from the Phase III trials.
CONCLUSION
Tedizolid phosphate is the first of the secondgeneration oxazolidinones to receive FDA approval and is currently indicated for the treatment of ABSSSI and under investigation for the treatment of hospital acquired pneumonia. While greatly similar to linezolid, tedizolid phosphate possesses more favorable pharmacokinetics, enhanced antimicrobial potency, and lower incidence of adverse effects including thrombocytopenia. Clinical experience with tedizolid, however, is largely limited to Phase II and III clinical trials, and careful consideration of therapeutic alternatives should be recommended. It remains to be seen if the in vitro activity of tedizolid against some linezolid-resistant isolates will prove clinically useful. 
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